The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Advances in menin inhibition for AML: experience with revumenib and recent approval of ziftomenib
David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses advances in menin inhibition for acute myeloid leukemia (AML), highlighting the real-world experience with revumenib and recent approval of ziftomenib. Dr Sallman emphasizes the promising data on combining menin inhibition with other therapies and its potential for measurable residual disease eradication. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, so I think menin inhibition has been the hottest topic for the past couple years. We now are one year post-approval of revumenib, and actually now just, you know, fresh off the press, we have ziftomenib approval and updated label for NPM1 mutant revumenib. So, you know, once we have it, we can really start to change the practice. And so, you know, I think incorporating menin inhibition and as we did with revumenib for KMT2A really should be throughout a patient’s journey...
Yeah, so I think menin inhibition has been the hottest topic for the past couple years. We now are one year post-approval of revumenib, and actually now just, you know, fresh off the press, we have ziftomenib approval and updated label for NPM1 mutant revumenib. So, you know, once we have it, we can really start to change the practice. And so, you know, I think incorporating menin inhibition and as we did with revumenib for KMT2A really should be throughout a patient’s journey. So I think the data already strongly support that unless you can get a patient on a trial, which we would highly recommend that frontline menin inhibition on top of AZA-VEN looks exciting. Actually, all of our patients treated in that setting have had ongoing durable remissions without relapse. And with cutting down the venetoclax, we’ve not really had later cytopenia toxicities. I think there’s a number of other places. Yes, it works on label, but you can think about MRD eradication. So it’s some patients go on only for MRD. And even at high depth, even down to 1 times 10 to the negative 5, we’re able to eradicate NPM1. Also thinking about post-transplant. So we had some patients get to their first transplant and even a couple get to their second transplant. Early incorporation of maintenance has looked quite favorable versus historical outcomes. And I think largely with combination therap revumenib has been very well tolerated we’ve not really had any discontinuations all but one which was more of an infectious issue that may have been or may not have been related so I think the bottom line is your revumenib both as monotherapy and maybe more exciting as combination approaches can really have sort of game-changing therapy throughout a treatment’s course. I think we’ll be looking forward to more data with this as well as with ziftomenib now that it has approval as well. But pretty excited by the revumenib data to date.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
